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ColonAbstract Ulcerative colitis is the chronic relapsing multifactorial gastrointestinal inﬂammatory
bowel disease, which is characterized by bloody or mucus diarrhea, tenesmus, bowel dystension,
anemia. The annual incidence of ulcerative colitis in Asia, North America and Europe was found
to be 6.3, 19.2 and 24.3 per 100,000 person-years. The major challenge in the treatment of ulcerative
colitis is appropriate local targeting and drug related side-effects. To overcome these challenges,
microparticulate systems seem to be a promising approach for controlled and sustained drug release
after oral administration. The main goal of this article is to explore the role of microparticles in
ulcerative colitis for the appropriate targeting of drugs to colon. There are different approaches
which have been studied over the last decade, including prodrugs, polymeric approach, time
released system, pH sensitive system, which show the site speciﬁc drug delivery to colon. Among
these approaches, microparticulate drug delivery system has been gaining an immense importance
for local targeting of drug to colon at a controlled and sustained rate. Combined approaches such as
pH dependent and time dependent system provide the maximum release of drug into colon via oral
route. This article embraces brieﬂy about pathophysiology, challenges and polymeric approaches
mainly multiparticulate systems for site speciﬁc drug delivery to colon in sustained and controlled
manner so that drug related side-effects by reducing dosage frequency can be minimized.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Inﬂammatory bowel diseases are the idiopathic chronic multi-
factorial inﬂammatory diseases of gastrointestinal tract, which
mainly include ulcerative colitis and Crohn’s disease (Talaei
et al., 2013). Small intestine and large intestine or colon are
the main regions involved in inﬂammatory bowel diseases,
which are marked by the chronic inﬂammation in speciﬁc
mucosal or transmural locations (Friend, 2005). Appropriate
local targeting is the main challenge in the treatment of ulcer-
ative colitis. For improved localization, a well designed drug
delivery system is beneﬁcial to enhance therapeutic efﬁcacy.
There are many approaches used for appropriate targeting like
pro drug approach, conjugate approach, and time released
system, pH dependent system, multiparticulate system,
nanoparticulate system, probiotic approach. Among all,
microparticulate system is one of the best approaches for con-
trolled drug delivery in speciﬁc site of inﬂammation. Micropar-
ticles are small free ﬂowing particles consisting of natural or
synthetic polymers having particle diameter ranging from 1
to 1000 lm. With the advancement in biotechnology, genom-
ics, lots of potent and speciﬁc therapeutics have been formed.
Due to various problems such as low solubility, poor stability,
narrow therapeutic index of many new drugs, there is a corre-
sponding need for safer drug delivery. The delivery should be
designed in such a way to provide active agent in right amount,at right time, to proper location in the body to increase patient
compliance and minimize side-effects. There is wide range of
particulate carrier system used for targeted drug delivery to
colon, which mainly includes microparticles, microcapsules,
nanoparticles, nanocapsules to overcome the disadvantages
of conventional drug delivery systems like increased risk of sys-
temic adverse drug reactions. To target drugs only to their
desired gastro-intestinal regions is really a great challenge.
Therefore, there is the need to design such a delivery system,
with a more effective drug targeting. Micro particulate carriers
like polymeric micro particles are found to have lots of appli-
cations in ulcerative colitis patients (Collnot et al., 2012).
Advances in the understanding of pathogenesis of ulcerative
colitis and mechanism of action of drug brought novel ideas
for drug targeting to speciﬁc site of action.
At present, the etiology of disease is not fully understood
but it has been hypothesized that various factors such as
genetic, Gut/environmental, psychosomatic, autoimmune, epi-
demiological are responsible for the development of ulcerative
colitis (Molodecky and Kaplan, 2010). Gut/environmental fac-
tors include immune/epithelial interactions, bacterial infec-
tions, and epithelial barrier functions. Epidemiological
studies include dietary habits, smoking habits, intake of drugs,
hormonal status, variations due to different climates, and
changes due to social circumstances. The inﬂammatory factors
can be examined through different cell signaling pathways,
Figure 1 A schematic diagram for ulcerative colitis.
460 Nidhi et al.inﬂammatory mediators such as tumor necrosis factor a
(TNF-a), Interleukin-1, Interleukin-6, Interleukin-12, Interleu-
kin-4, Interleukin-10 and Interleukin-11, and Eicosanoids pro-
ﬁles (Carter et al., 2004). Severe form of ulcerative colitis leads
to colon cancer. Chronic inﬂammation generated by the pro-
duction of reactive oxygen species leads to generate dysplasia,
which further turns into CAC, i.e., colitis associated colorectal
cancer, which is a severe form of ulcerative colitis (Rogler,
2014). Therefore, there is the high risk of colon cancer in
patients with ulcerative colitis (Navaneethan et al., 2013). This
risk is increasing every year. Urban and western industrialized
regions are mainly affected by these diseases rather than rural
areas (Thippeswamy et al., 2011). Ulcerative colitis is generally
authenticated by mucosal inﬂammation which generally
extends from the proximal region of colon to rectum. In ulcer-
ative colitis, with the inﬂux of neutrophils in lamina propia,
there is the localized collection of pus cells surrounded by
inﬂamed tissue and depletion of mucin followed by production
of inﬂammatory mediators like cytokines. Conversely, CD
does not restrict to a conﬁned region and can occur in any part
of GIT, where the accompanying inﬂammation is described as
irregular/patchy, segmented, and transmural. Most commonly,
the terminal ileum exhibits early lesions on or near Peyer’s
patches. In earlier studies, it has been reported that smoking
is beneﬁcial in ulcerative colitis, whereas it shows a negative
effect on Crohn’s disease (Botoman et al., 1998).
There are various conventional and unconventional thera-
pies used for the treatment of ulcerative colitis include amino-
salicylates, glucocorticoids, immunomodulators, etc. These
therapies need to be administered frequently to patients, which
reduces patient compliance and can cause systemic side-effects.
Thus, microparticles are found to be a promising approach for
controlled and site speciﬁc drug delivery, which minimize dos-
age frequency and improve patient compliance.
1.1. Signs and symptoms of ulcerative colitis
The chief initial symptoms of onset of ulcerative colitis consists
of severe abdominal pain, tenesmus, anorexia, bloody or
mucous diarrhea in contrast to Crohn’s disease, which does
not show any bloody diarrhea (Lee et al., 2013; Liang,
2002). The severe symptoms include weight loss, tachycardia,
anemia, rectal bleeding, and bowel distension (Meier and
Sturm, 2011). According to the severity of the disease, ulcera-
tive colitis is divided into different categories i.e., extensive,
distal, proctosigmoiditis, ulcerative proctitis. The schematic
diagram which brieﬂy explains the ulcerative colitis is given
in Fig. 1.
The global estimates of UC are known to be varied by geo-
graphic, environmental, socio-economic characteristics and are
increasing day by day (Eisen and Sandler, 1994). Most of the
peak incidences occur in the young people between the age
of 10–40 years. It has been estimated that up to 2,40,000 peo-
ple in UK, 1.4 million in United States and 2.2 million in Eur-
ope are affected by ulcerative colitis. Inﬂammatory bowel
disease can affect at a person of any age and can continue
throughout their life as it does not have any permanent cure
(Cosnes et al., 2011). Therefore, there is the need of adminis-
tering drug for life time for the maintenance of health related
quality of life (Lautenschla¨ger et al., 2013b). In UC, sites of
inﬂammation extend to the more proximal regions of the colonover time. Usually, rectum is also involved. Whereas in CD,
site of inﬂammation is usually distal ileum Table 1 shows com-
parison of Crohn’s disease vs. ulcerative colitis (Botoman
et al., 1998).
1.2. Epidemiology of ulcerative colitis
In western Europe, Asia and North America, UC has an
annual incidence of approximately 24.3 per 100,000 popula-
tion per year, 6.3 per 100,000 population per year and 19.2
per 100,000 population per year, respectively Whereas,
Crohn’s disease has less incidence as compared to UC i.e.,
approximately 12.7 per 100,000 population per year in Europe,
5.0 population per year in Asia and 20.2 per 100,000 popula-
tion in North America. All around the globe, IBD is becoming
a global disease because of increasing incidences and preva-
lences of it with respect to time. There are very lower inci-
dences in Asia, Africa and South America (Molodecky et al.,
2012). In the United States, it has been estimated that more
than 1 million individuals are suffering from IBD, among
which, 100,000 are children. IBD occupied 5th rank among
the most prevalent gastrointestinal diseases (Stein et al., 1998).
1.3. Multifactorial pathogenesis of ulcerative colitis
Ulcerative colitis (UC) is a chronic, relapsing intestinal inﬂam-
matory disorder of the colon, with variable distribution but
limited to the distal bowel (distal colitis and proctitis) in
60% of cases. UC has multifactorial etiology that may result
in either primary immunological dysfunction or an inappropri-
ate pathological immunological response to an environment.
e.g., commensal intestinal microorganisms. The ﬁrst cause is
the dysregulation of immune system which further leads to
excessive immune responses to normal microﬂora. Secondly,
epithelial cell abnormalities and changes in composition of
gut microﬂora facilitate an abnormal mucosal immune
response (Strober et al., 2007). Thirdly, impaired gene expres-
sion i.e., mutation of gene named CARD15/NOD2, located on
Chr 16 and other genes named OCTN 1 and 2 on Chr 5, in case
of Crohn’s disease (Ardizzone and Porro, 2002).
The etiology of idiopathic inﬂammatory bowel diseases like
ulcerative colitis and Crohn’s disease is found to be an enigma
Table 1 Comparision of Crohn’s disease vs. ulcerative colitis.
S. No. Features Ulcerative colitis Crohn’s
1. Site of action Extending from rectum proximally to entire colon
only
Any part of GIT (mainly ileum is involved
2. Symptoms Diarrhea, wt. loss, malnutrition and other
extraintestinal manifestations (JSEM), smoking
improves condition
Diarrhea, abdominal pain, wt. loss, malnutrition,
growth failures in kids, smoking make it worse
3. Pathology and
complications
Mucosal inﬂammation, if get severe can cause colon
cancer. Fistulas, abscesses and strictures absent
Transmural inﬂammation, non caseating granulomas,
ﬁstulas, abscesses, perianal involvement and strictures
are common. Toxic megacolon absent
4. Cytokine response Associated with Th17 Associated with Th2
5. Distribution Continuous distribution Discontinuous
6. Drugs used 5-Amino salicylic acid, Hydrocortisone,
Sulfasalazine, Budesonide,
Balsalazide, Inﬂiximab, Prednisolone,
Azathioprine and mercaptopurine Sulfasalazine, Olsalazine,
Mesalazine and Balsalazide, Inﬂiximab
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colitis is a local inﬂammatory bowel disorder in which contin-
uous mucosal inﬂammation extends from the rectum toward
the cecum, and is generally associated with excess IL-13 pro-
duction whereas, Crohn’s disease is a relapsing inﬂammatory
disorder which may involve any part of the gastrointestinal
tract, but mainly terminal ileum and colon are involved having
discontinuous ulceration and inﬂammation involving
granulomas, which is associated with excess of production of
IL-12/IL-23 and IFN-c/IL-17 as shown in Fig. 2 (Fuss et al.,
2004). Fig. 2 shows the diagrammatic scheme of pathogenesis
of ulcerative colitis by following pathway of T-Lymphocyte
activation. Previous studies reported that alterations in
intestinal barrier function may play a crucial role in the devel-
opment of ulcerative colitis. Some authors reported that
abnormally increased intestinal permeability is the etiologic
factor in ulcerative colitis and contributes to disease perpetua-
tion. Thus disrupted barrier function of epithelial wall leads to
an increase in the permeability of mucosa for luminal antigens,Figure 2 Diagrammatic scheme of pathogenesis of inﬂammatory bbacteria/microorganisms, and loss of water and electrolytes,
thereby, stimulating the inﬂammatory process (Stein et al.,
1998). Due to this disruption of barrier, various electrolytes
and water have been lost from the body via epithelium. In
addition to this, the polarity of damaged intestinal epithelial
cells has also been lost which results in apical expression of
transferring receptor protein, whose expression is generally
enhanced on both apical and basolateral region of enterocytes
in inﬂammatory mucosa of IBD patients (Harel et al., 2011).2. Major challenges in the treatment of ulcerative colitis
The major challenge in the treatment of ulcerative colitis is the
reduction of drug related side-effects by doing site speciﬁc drug
delivery to colon. Furthermore, long term medication produces
lots of side-effects, which negatively affect the quality of life of
ulcerative colitis suffered patients. To design a delivery system,
which delivers the maximum amount of drug to speciﬁc site atowel disease by following pathway of T-Lymphocyte activation.
Table 2 List of drugs used for the treatment of ulcerative colitis.
Classes of drugs Trade name Marketed formulations Adverse eﬀects Dose
1 Aminosalicylates Sulfasalazine Azulﬁdine Delayed release tablet Agranulocytosis,
pancreatitis, interstitial
nephritis
4–6 g/day divided qid
Mesalamine Asacol Eudragit S 100 coated tablet
(dissolves at pH 7)
Hepatitis, male infertility,
arthralgia, pneumonitis
2–4 g/day divided bid-qid
Olsalazine (it should be
taken after having meals)
Dipentum Hard gelatine capsules Stomach upset, bloating, loss
of appetite, blurred vision,
headache, pain in joints,
dizziness
1.5–3 g/day divided bid qid
Balsalazide Colazal Tablet Headache, abdominal pain,
upset stomach, diarrhea,
vomiting, joint pain,
diﬃculty falling or staying
asleep, tiredness
2.25 g 3 times daily for 8–
12 week
2 Corticosteroids Budesonide Entocort Eudragit L coated beads Dry or irritated mouth or
throat, cough, diﬃcult or
painful speech, neck pain,
stomach pain
9 mg/day
Prednisolone Deltasone,
Orasone
Tablets of 2.5, 5, 10, 20 and
50 mg and oral solution/
syrup
Hyperglycemia,
hypertension, electrolyte
disturbances
5–50 mg per day
Dexamethasone Dexasone,
Diodex,
Decadron
Tablets, Elixirs and solutions Cataracts, osteoporosis,
myopathy
Tablets – 0.25–6 mg
Elixir – 0.5 mg/ml
Solution – 0.5, 1 mg/5 ml
3 Immunosuppressive
agents
Azathioprine,
Methotrexate
Imuran Tablet Hyperglycemia,
hypertension, electrolyte
disturbances, cataracts
50 mg
Rheumatrex,
Traxell
Solution given i.v 25 mg/ml
4 Antimicrobial
agents
Metronidazole Flagyl Extended release tablets
750 mg, capsule 375 mg,
cream 0.75 and 1%, lotion
0.75%, gel 0.75% and 1%
injection
Urticaria, glossitis; long-term
use may develop paresthesia
750 mg orally three times
daily for 5–10 days
Ciproﬂoxacin Cipro, Proquin
XR
Tablets 250, 500 and 750 mg Diarrhea, vomiting and rash.
Other side eﬀects (e.g.
headache, abdominal pain,
pain in extremities, injection
site reaction, cardiovascular,
Gastrointestinal, etc.) In less
than 1% of the patients
500 mg twice daily
Extended released (XR) 500
and 1000 mg
Microcapsules for
suspension 250 mg/5 ml
Injections 200 mg/100 ml
5 Inhibitors of TNF-a Inﬂiximab Remicade Powder for intravenous
injection
Acute infusion reactions 100 mg
Adalimubab Humira Preﬁlled glass syringe Serum sickness, increase in
serious infections (e.g. sepsis,
pneumonia, tuberculosis)
20 mg/0.4 ml and 40 mg/
0.8 ml
4
6
2
N
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h
i
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really a great challenge (Kim and Pack, 2006). There are many
drugs which are used for the treatment of inﬂammatory bowel
diseases showing adverse effects like peptic ulcers, diarrhea,
nephro and hepatotoxicity, glaucoma, vomiting, Cushing’s syn-
drome, etc. (Buchman, 2001; Ransford and Langman, 2002;
Rutgeerts et al., 2005; Papadakis et al., 2005).
Over the past two decades the major challenge for scientists
is to target the drugs speciﬁcally to the colonic region of GIT
(Sowmya et al., 2012). Another challenge for children with
IBD, mainly Crohn’s disease, is the impairment of skeletal
and growth development due to lack of balanced nutrition.
In addition, inﬂammatory mediators such as cytokines cause
some mutations in hormonal axes, which directly inﬂuence
growth. To overcome these problems, proper nutrition and
appropriate anti-inﬂammatory therapy are found to be the
best option.
3. Various drugs used for the treatment of ulcerative colitis
The cure of UC depends upon the severity of disease, its sub-
type, and its pre-existing illness. The most commonly used
drugs for its treatment are anti-inﬂammatory agents which
mainly include 5-amino salicylates (mainly used in UC) like
olsalazine, mesalazine and balsalazide, which is used for the
cure of mild to moderate attacks and to maintain remission
in UC and immunosuppressive agents which mainly include
azathioprine, 6-mercaptopurine, methotrexate, cyclosporine,
tacrolimus calcineurin inhibitors (Isaacs et al., 2005). Other
class of drugs which can also be used are corticosteroids, like
prednisolone and anti-TNF-a-antibodies for moderate to
severe conditions of Ulcerative Colitis (Taylor and Irving,
2011). In case of refractory and fulminate disease stages, sur-
gery may serve as a better option for IBD patients (Neurath
and Travis, 2012).
3.1. Conventional/unconventional drug therapy for UC
3.1.1. Conventional drug therapy
3.1.1.1. Amino salicylates. Sulfasalazine is the ﬁrst class drug of
antibiotics, consists of 5-aminosalicylic acid (5-ASA) and sul-
phapyridine in which 5-ASA shows anti-inﬂammatory proper-
ties, while sulfapyridine shows anti-bacterial properties. The
exclusive mechanism of action of 5-aminosalicylates involves
the stimulation of class of nuclear receptors which generally
control the inﬂammation and cell proliferation. It helps in
reducing the production of chemoattractant leukotrienes and
inhibits the cellular release of interleukin-1 and 2 (Zhou
et al., 1999).
It also inhibits the transcriptional activity of nuclear-factor
jB, that regulates the genes responsible for immunity and
inﬂammation. It is extensively metabolized in liver, therefore,
it is having poor systemic bioavailability. Baron et al. (1962)
reported that this class of drugs induce remission in 40–80%
of patients (Riley et al., 1988; Baron et al., 1962). It is used
in the form of oral sustained release tablet or granule and
locally applied in the form of suppositories, enemas etc., but
its usage is limited because of sulphapyridine-related intoler-
ance (Egan et al., 1999). Most of studies reported that cipro-
ﬂoxacin is the commonly used antibiotic for moderate to
severe UC (Turunen et al., 1998). Table 2 shows list of drugsused for the treatment of ulcerative colitis. Approximately
80% of remission can be achieved within ﬁrst 2–4 weeks after
having Ist line therapy.
3.1.1.2. Glucocorticoids. These drugs act via glucocorticoid
receptor in the cell nucleus and modulate immune response
but due to steroidal nature of these drugs, they can develop
corticoid dependency and corticoid resistance which limit their
applicability in ulcerative colitis (Ford et al., 2011). Such
ﬁndings need steroid-sparing medication in IBD. In previous
studies, it has been found that budesonide 9 mg per day when
formulated as a pH and time dependent dosage form is much
effective than oral daily dose of 4000 mg of 5-ASA for
remission induction in IBD. These drugs are used for mild to
moderate conditions of IBD. But in severe form of IBD and
for patients who do not respond to corticosteroids, Immuno-
suppressive drugs like azathioprine, 6-mercaptopurine, metho-
trexate, cyclosporine, tacrolimus etc. are the next line of drugs
and play an important role for IBD. But safety proﬁle of this
therapy is still conﬂicting (Isaacs et al., 2005).
3.1.2. Unconventional drug therapy
3.1.2.1. Biological therapies. The recent insights into the tech-
niques of molecular biology lead to ﬁnd new discoveries/thera-
pies for the management of inﬂammatory bowel disease. These
agents are classiﬁed as biological therapies which include gene
therapy, recombinant peptides and proteins, antibody based
therapies like monoclonal antibodies, which are mainly
TNF-a inhibitors i.e., Inﬂiximab, a chimeric IgG1 comprising
75% humans and 25% murine sequences is currently used for
the treatment of CD and biological preparations such as immu-
noglobulins and vaccines (Ardizzone and Porro, 2002). TNF-a
inhibitors like inﬂiximab (previously known as cA2, ada-
limumab and certolizumab pegol play an important role in
the treatment for severe chronic disease stages. The mechanism
of action of inﬂiximab is to inhibit the biological activities of
TNF-a or interaction of TNF-a with its receptors. In addition
to inﬂiximab, other two drugs i.e. adalimumab and certo-
lizumab have also been approved by FDA for IBD and having
the mechanism same as that of inﬂiximab (Siegel et al., 1995).
The treatment for IBD requires a balance between high thera-
peutic efﬁcacy and reduced adverse drug reactions. A promis-
ing strategy to enhance the therapeutic beneﬁt of established
drugs is the utilization of particle carrier systems, which release
active agents speciﬁcally at the site of intestinal inﬂammation.
3.1.2.2. Immunomodulators. New immunomodulators devel-
oped for the management of IBD are thalidomide, tacrolimus,
mycophenolate mofetil. The mechanism of action of thalido-
mide is the reduction of TNF-a production by increasing the
destruction of TNF-a messenger RNA encoding protein,
which inhibits transcription and translation (Sandborn et al.,
2001). It also inhibits the production of IL-12, responsible
for the regulation of cellular immune responses (Moreira
et al., 1993; Moller et al., 1997).
4. Role of microparticulate carrier for targeted drug delivery to
colon for ulcerative colitis
Polymeric microparticles have turned out to be a promising
approach as a targeted drug delivery system for the treatment
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strategy is to target the maximum concentration of active
agents in inﬂamed intestinal tissues by using selective delivery
to achieve therapeutic efﬁcacy while simultaneously reducing
adverse effects. In addition to this, such targeted delivery
system must meet the conditions for complete biodegradation
and high biocompatibility without pro-inﬂammatory proper-
ties (Lautenschla¨ger et al., 2013a). Controlled release drug
delivery system is one of the most efﬁcient methods to over-
come most of the difﬁculties associated with other methods
of administration. Controlled release drug delivery includes
carriers such as polymer-based disks, microparticles, nanopar-
ticles, pellets in which drug gets encapsulated and release at
controlled rates for relatively long periods of time. Such kind
of systems often show several advantages over other methods
of administration.
 First advantage is the drug release rates can be adjusted
according to the needs of a speciﬁc application; for
example, providing a constant rate of delivery or pulsatile
release.
 Second, controlled release systems also protect drugs, espe-
cially proteins, from degradation that are otherwise rapidly
destroyed by the body. Finally, by using controlled release
systems, frequent (daily) dosing can be replaced by giving
once per month injection, which ultimately increases patient
comfort and compliance.
In recent years, Particulate drug carriers include micropar-
ticulate, nanocarriers have been gaining an immense impor-
tance due to their wide advantages over existing systems
(Gilhotra et al., 2009). These particulate systems are unique
in terms of their particle size, as optimum particle size of car-
rier for localization of drug should be in the range of 5–15 lm
to increase the residence time of drug in the colonic region.
Particle size of this range is able to adhere at the site of action
and get accumulated in the targeted region. But in some stud-
ies, it has been reported that for IBD therapy, microparticles
should be in size range of 10–300 lm to target speciﬁcally to
the inﬂamed region of colon (Collnot et al., 2012). Selection
of carrier is very important for particular drug i.e., either
hydrophilic or lipophilic. It depends on the diseased condi-
tions as well as on the physico-chemical nature of drug.
Among recent techniques used for colon speciﬁc delivery,
micro and nano-particles are well known for achieving site
speciﬁcity, increasing drug stability via encapsulation. Opti-
mal size range of carrier system for proper localization and
accumulation in targeted region is between 4 and 15 lm.
Most of the drugs used in the treatment of IBD show strong
adverse effects due to systemic bioavailability. But targeting
drug to the localized area of intestine can reduce the systemic
side-effects.5. Various microparticulate polymeric approaches used for
targeting drugs to colon for the treatment of ulcerative colitis
Colon targeted drug delivery via pH dependent, time depen-
dent, microﬂora or enzyme activated system, mucoadhesive
and pressure controlled based system have attracted great
interest for the treatment of systemic as well as local disease
(Patel et al., 2007).5.1. pH dependent polymeric approaches
The most commonly used pH dependent polymers are CAP
(Cellulose acetate phthalates), CAT (cellulose acetate phthal-
ate), HPMCP 50 and 55, (Hydroxypropylmethyl cellulose
phthalate), Eudragit S 100, Eudragit L (Copolymers of metha-
crylic acid and methacrylate), Eudragit FS, Eudragit P4135 F,
For the development of effective delivery system, the threshold
pH of polymer and their solubility in different pH conditions
should be well known (Newton et al., 2012). According to pre-
vious reported studies, there are various ﬂuctuations in pH of
colon due to some reasons. In normal healthy individuals, there
is increase in pH from duodenum (pH 6.6 ± 0.5) to terminal
ileum (pH 7.5 ± 0.4) and a decrease in cecum (pH
6.4 ± 0.4), then a slow rise from right to left colon with ﬁnal
value (pH 7.0 ± 0.7). But it has been reported that these poly-
mers are unable to release the drug to large intestine as these are
pH dependent and leads to premature release in small intestine
or very less amount release in colon because of varying transit
time of small intestine (Ashford et al., 1993). Therefore, multip-
articulate drug delivery systems formulated as single layered or
multi-layered product have a great potential for the reproduc-
ible drug release in inﬂamed sites of the colon due to less inter-
subject variations (Chourasia and Jain, 2003; Singh, 2007).
Some examples for this delivery system are 5-amino sali-
cylic acid coated with Eudragit S 100, marketed as Asacol tab-
let has been prepared for its pH dependent release (Schroeder
et al., 1987). Lialda, a locally acting delayed release tablet
under the common name mesalamine, has been approved in
January, 2007, in which drug is completely dispersed in lipo-
philic matrix. According to another study by Mahkam and
Vakhshouri (2010), 5-aminosalicylic acid loaded methacrylic
acid/perlite composites have been prepared which show pH
dependent release.
Some other marketed formulations of multiparticulate pH
dependent systems are commercially available such as Budeno-
falk and Entocort. In budenofalk, pH dependent polymers like
Eudragit RL, Eudragit S, Eudragit L, etc. were used whereas, in
Entocort, delayed release polymers like ethylcellulose were used
for time dependent release (Rodri´guez et al., 1998). In other
study, Makhlof et al. (2009), prepared PLGA coated budeso-
nide loaded nanospheres for sustained release at pH 7.4.
But, due to lack of site speciﬁcity of pH dependent poly-
mers in colon, there exists a controversy for reliability of tar-
geting method. To remove such limitation, there is the need
of combining two polymers i.e., one is delayed release/time
controlled and other is pH dependent, so that maximum
amount of drug releases in the colon and show its therapeutic
effect. Hashem et al. (2013), combined both time and pH
dependent system for targeting prednisolone microspheres to
colon. He found that Eudragit S, an enteric coated polymer
starts dissolving at pH more than 6, which causes the lack of
site speciﬁcity of drug at colonic region. Therefore, he com-
bined both Eudragit S 100 and ethylcellulose, as only 20%
drug released in small intestine while due to delayed release
polymer, rest 80% will release in colon.
5.2. Time-dependent polymeric systems
Time dependent systems such as sustained release or delayed
release system found to be a better approach for site speciﬁc
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eased conditions, which ultimately lead to either premature
release of drug in small intestine or very less amount will be
released in the colon (Lee and Wilson, 2003; Hinton et al.,
1969). For the successful drug delivery, one should have the
knowledge of gastric transit time of dosage form. It varies
between 15 and 180 min. in case of non-disintegrating single
dosage form, where as it is more constant for small intestine
in between 3–4 h and average transit time in the colon is
47 h in women and 33 h in men. But there are some intersub-
ject variations in GI transit times that depend on amount of
food intake, peristalsis movement in stomach. Due to these
variations, time dependent system alone is not suitable for
ideal drug delivery to colon. For overcoming such limitation
of this system, two approaches were combined i.e., pH depen-
dent and time controlled which serve to improve site speciﬁc
drug delivery to colon (Fukui et al., 2000).
El-Gibaly (2002), formulated ketoprofen-loaded Zn pecti-
nate gel (ZPG) microparticles along with pectin mixtures in
form of tablets and found that there was the extended release
of drug from ZPG microparticles with pectinate microparti-
cles, which contained 2–3% w/v pectin, 2.75% w/v Zn
(CH3COO)2 and 2.5% w/v drug. It was also concluded that
untableted ZPG microparticles retard the release of ketoprofen
in simulated intestinal ﬂuid (pH 7.4), which made it a
promising controlled-release carriers for colon-targeted drug
delivery.
5.3. Biodegradable polymeric systems
Various attempts have focussed on the recent applications of
polysaccharides for colon speciﬁc drug delivery. The extensive
growth of colonic microﬂora is the characteristic feature of
colon which explored it for site speciﬁc colonic drug delivery.
This vast anaerobic microﬂora further produces no. of hydro-
lytic as well as reproductive enzymes such as nitroreductase,
azoreductase, glucuronidase, deaminase, xylosidase (Scheline,
1973) which made it suitable for site speciﬁc drug delivery.
Most commonly used polysaccharides which are degraded by
these colonic enzymes are chitosan and chondroitin (obtained
from animal origin), pectin, guar-gum and inulin (from plant
origin), alginates (from algal), dextran (from microbial origin),
amylase. Because of its excellent and fascinating features such
as biodegradability, high stability, safe, non-toxicity, cheap,
natural origin, gel forming and wide distribution in the world
made it suitable for colon targeted drug delivery (Philip and
Philip, 2010). Description of polysaccharides is given below.
5.3.1. Guar gum
Guar gum is an outstanding eco friendly non ionic polysaccha-
ride obtained from the seeds of Cyamopsis tetragonolobus
belonging to the leguminous family . Chemically, it consists
of mannose backbone i.e., D-Mannopyranosyl along with gal-
actose side branching i.e., D-glucopyranosyl side branching.
Patel et al. (2007) developed guar gum microspheres of
mebeverine hydrochloride for local release of drug in the colon
in the form of tableted microspheres (Patel et al., 2007). He
found that in vitro study of microspheres may lead to prema-
ture release in upper GIT. Therefore, they compressed micro-
spheres into tablets so that mebeverine remain intact in
tableted form in lower GIT. As it reached to colon, entericcoating removed and microspheres were dispersed and showed
its therapeutic beneﬁcial in colon targeting.
In another study, Sarkar et al., formulated guar gum micro-
spheres by emulsion cross linking technique, which is further
coated with Eudragit S 100. He found that 7–11% of drug
was released in ﬁrst four hours while 80% of drug released
in 8–10 h, that shows its maximum drug release in desired colo-
nic region.
5.3.2. Chitosan
Chitosan a functional linear co-polymer consisting of 2-amino-
2-deoxy-D-glucose and 2-acetamido-2-deoxy-D-glucose unit
links with b-(1–4) bonds is the most abundantly found natural
polysaccharide after cellulose, derived from chitin. It carries
positive charge and reacts with the negatively charged surface
including DNA and polymers to achieve site speciﬁc drug
delivery. As chitosan is having glycosidic linkages, it undergoes
glycosidic hydrolysis by microbial enzymes present in the
colon which leads to loss of mechanical strength and molecular
weight (Ghandehari et al., 1997). In one study, Saboktakin
et al., 2011 prepared carboxymethyl starch–chitosan nanopar-
ticles for targeted drug delivery system to colon by complex
coacervation process and found that average drug entrapment
was 81 ± 1.86% in nanoparticle because of higher crosslinked
gel like structure (Saboktakin et al., 2011). In this study, it was
concluded that the amount of drug released from nanoparticles
decreased with increase the cross linking time. Table 3 shows
design approach by using different polymers.
Gawde et al., 2012 formulated mucoadhesive microspheres
of deﬂazacort for the treatment of ulcerative colitis by using
chitosan, as a mucoadhesive polymer with the coating of
Eudragit S 100. He found that chitosan coating of deﬂazacort
improves the bioavailability of the drug by crosslinking it with
glutaraldehyde.
In another study, Sareen et al. (2014) formulated curcumin
loaded Eudragit-coated chitosan microspheres by emulsion
crosslinking method. He concluded that curcumin loaded
chitosan microspheres without Eudragit S 100 coating showed
burst release in ﬁrst 4 h, while Eudragit coated microspheres
prevent the drug to release early and showed controlled release
of drug up to 12 h, which conﬁrms the potential of delivery
system for ulcerative colitis.
Chandra et al. (2012), developed satranidazole loaded
Eudragit microspheres by oil in oil solvent evaporation
method. In this article, it was concluded that coating of
Eudragit prevents drug release in stomach, while maximum
release was at pH 7.4.
Rasool et al. (2012), tried to develop the modiﬁed release
dosage form of metoprolol, a cardioselective b-blocker to
reduce the dosage frequency as well as side-effects. Eudragit
FS was used for pH dependent release in intestine. In this
study, it was concluded that according to drug release data,
zero order model was found to be best suited and shows con-
trolled release delivery. Table 4 shows a brief description of
reported microparticles formulated by using various polymers
by different methods (see Table 5).
6. Mechanism of microparticle uptake in ulcerative colitis
The mechanism of microparticles for proper site speciﬁc drug
delivery is based on complete knowledge of mechanism of drug
Table 3 Various advantages, disadvantages and applications of methods used for ulcerative colitis.
Polymer Formulation and design approach References
Eudragit P-4135 F, a new pH sensitive polymer, dissolve
at pH > 7.2
Enteric coating polymer used to prepare
microparticles of tacrolimus, an immunosuppressant
drug used mostly in ulcerative colitis
Lamprecht et al. (2005)
Eudragit L30 D-55, copolymer of methacrylic acid and
ethyl acrylate (dissolves at pH 5.5). Eudragit FS 30 D,
copolymer of methacrylic acid, methacrylate and
methylmethacrylate (dissolves at pH 7 or above)
Enteric coated HPMC capsules of paracetamol
designed to achieve intestinal targeting
Cole et al. (2002)
Eudragit L100 (dissolve pH> 6) Enteric coated tablets of mesalazine for the
treatment of Crohn’s disease
Tromm et al. (1998)
Ethylcellulose, inert hydrophobic polymer and Eudragit
S 100 soluble at pH 7
Enteric coated time released-matrix tablets for colon
targeting
Alvarez-Fuentes et al. (2004)
Ethylcellulose, hydrophobic and hydroxypropylmethyl
cellulose phthalate
Combination of ethylcellulose and HPMC used for
the preparation of empty pressure-controlled colon
delivery capsules of Fluorescein
Jeong et al. (2001)
466 Nidhi et al.as well as disease. For improved localization and increased
residence time of drug at the site of inﬂammation, optimum
particle size should be between 4 and 15 lm (Coppi et al.,
2001, 2002; Lamprecht et al., 2001a,b). Particle size in that
range gets accumulated in the inﬂamed sites even without mac-
rophage uptake. Particles below size range of 10 lm increase
residence time at the inﬂamed region, while with further size
reduction, clearance get minimized at size of approximately
100 nm. The ﬁrst important layer covering colonic mucosa is
the mucus gel layer. To achieve high localization in Payer’s
patches, intestinal lymphoid tissue and lamina propria, there
is the need to overcome such barrier/layer. After crossing such
mucosal layer, particles have to be translocated across M cells
and enterocytes depending upon size of particles. The
mechanism of this size dependent translocation across colono-
cytes involves following process: (1) Particles of size range
<500 nm show endocytotic uptake through endocytosis. (2)
Particles of size <5 lm adsorbed by M cells of Peyer’s patches
show lymphatic uptake. (3) By using mucoadhesive coating
polymers, bioadhesion of microparticles/nanoparticles is
increased. In case of UC, as the disease severity increases, pro-
tective mucus layer starts becoming thinner. This pathophysi-
ology of mucus layer increases the mucosal permeability and
helps in the proper location at its inﬂamed sites. According
to Nixon et al., microparticles having size range of 2–5 lm
remain in payer patches for longer period of time and show
less systemic distribution and improve local inﬂammation
(Lamprecht et al., 2001b). Fig. 3 shows (1) Uninﬂammed
mucosa: (a) Particles of size <500 nm show endocytotic
uptake, (b) particles of size <5 nm show lymphatic uptake.
(2) Inﬂammed mucosa: Increased particle uptake due to leaky
epithelium.7. Various methods of preparation of microparticles
Microparticles should be biocompatible and biodegradable
and have the ability to deliver drug speciﬁcally to the conﬁned
area rather than other sites. It depends upon the properties of
polymer used, method of preparation and various other fac-
tors which effect its surface properties. There are various meth-
ods used for the preparation of microparticles as mentioned
below.7.1. Spray drying technique
This technique is used for the preparation of polymeric
blended microspheres having the size range from 1 to
100 lm. In this method, polymer is dissolved in volatile
organic solvent like DCM or acetone. Then core material is
dispersed in this polymeric solution. This dispersed phase is
atomized in a spray chamber under hot air, which leads to
the formation of ﬁne mist from which solvent evaporates
instantaneously. Thus microparticles get separated by cyclone
separator, present just beside spray chamber, while whole sol-
vent is removed by vacuum drying.
Mathew et al. (2008); prepared the ketoprofen loaded PCL
[poly(epsilon-caprolactone)] and cellulose acetate butyrate
(CAB) by using this technique. Varshosaz et al. (2011), pre-
pared the microcapsules of budesonide with different molecu-
lar weight dextran at different ratios and found that 1:10 drug
to polymer ratio is effective in targeting drug to colon when
compared with mesalazine suspension.
7.2. Single emulsion technique
In thismethod, drug is dissolved in aqueousmedium, which acts
as dispersed phase, is dropped into oil phase, which acts as con-
tinuous phase. A single emulsion will form, which is further sta-
bilized by addition of either crosslinker or by heating. The most
commonly used chemical crosslinkers are formaldehyde, glutar-
aldehyde, epichlorohydrin, etc. Example of this technique is
Gelatin A microspheres by Jeevana and Sunitha (2009).
Raj et al., formulated and evaluated 5-Flourouracil loaded
chitosan microspheres with the coating of Eudragit S100 by
using oil in oil emulsiﬁcation method using core:coat ratio is
5:1. It was concluded that with the increase in polymer concen-
tration, rate of drug release decreased. Thus, Eudragit S 100
coated chitosan microspheres prepared by single emulsiﬁcation
technique provided controlled release drug delivery.
Dashora and Jain (2009), formulated pectin-prednisolone
microspheres for the treatment of ulcerative colitis by using sin-
gle emulsion-dehydration technique. In this study, two types of
microspheres, one is simple prednisolone loaded pectin micro-
spheres; while other is Eudragit coated pectin-prednisolone
microspheres were prepared. It was concluded from this study
Table 4 Various polymers used for the treatment of ulcerative colitis.
Microparticle
formulation
Polymer used Size Method Inference References
1. PEG-functionalized
microparticles
Fluorescent chitosan,
PEG and PLGA
Diameter of
3000–300 nm
Solvent evaporation
technique
Fluoresceinamine-labeled-
PEG-functionalized
microparticles showed
increased translocation
through inﬂamed mucosa
Lautenschla¨ger et al.
(2013b)
2. Multiparticulate
system
Cellulose acetate
butyrate coated by
Eudragit S
60–110 lm Emulsion solvent
evaporation
technique
With the use of
hydrophobic polymer i.e.,
CAB, hydrophobic drug
i.e., Ondansetron and
budesonide get diﬀuse in
the controlled manner
Rodrı´guez et al.
(1998)
3. Eudragit coated
chitosan-prednisolone
conjugate microspheres
Chitosan, succinyl
prednisolone, Eudragit
L100
1.5–26.6 lm Emulsiﬁcation and
evaporation method
Prednisolone loaded Ch–
SP-MS/EuL reduces the
toxic side-eﬀects of drug
Oosegi et al. (2008)
4. Ethyl cellulose coated
pectin alginate
microspheres
Ethyl cellulose, pectin,
alginate
500–700 lm Ionotropic-external
gelation technique
Ethyl cellulose-coated
pectin microspheres of 5-
ﬂuorouracil prevents the
drug release in the upper
part of GIT
Ramana and
Krishna (2011)
5. Ethyl cellulose coated
gelatine 5-Amino
salicylic acid
microspheres
Gelatin, ethyl cellulose 50–400 lm Solvent evaporation
method
As gelatin is hydrophilic,
coating of ethyl cellulose
makes it a delayed drug
delivery system in which
30% drug will release from
microspheres within ﬁrst
6 h, which makes it
suitable for maximum
drug delivery to colon
Atyabi et al. (2010)
6. Magnetic microspheres Eudragit S100, ethyl
cellulose, chitosan
153–200 lm Solvent evaporation
technique
Magnetic microspheres Kakar et al. (2012)
7. Biodegradable
mesalamine containing
microspheres
PLGA coated
mesalamine
microspheres
1.15 lm Emulsiﬁcation
solvent evaporation
method
PLGA-mesalamine
microspheres provides the
controlled drug delivery as
compared to suspension of
the same drug, which
shows eﬀective targeted
drug delivery to inﬂamed
site in ulcerative colitis
Mahajan et al.
(2011)
8. Naproxen sodium
using sodium alginate
and Eudragit S100 as
mucoadhesive and pH-
sensitive polymer
Eudragit S-100 and
sodium alginate
454.26 lm By cross-linking
with CaCl2
Enteric coated
microspheres showed a
longer residence time in
colon after removing its
coating due to better
mucoadhesion properties
of sodium alginate
Chawla et al. (2012)
9. 5-Florouracil
microspheres for colon
delivery
Chitosan, Eudragit S 100 206.23 lm Emulsion
dehydration method
and emulsion
solvent evaporation
method
Eudragit S 100 coated
chitosan microspheres
reduces the side-eﬀects of
drug caused by its
absorption from upper
part of GIT when given in
conventional dosage form
Raj et al. (2013)
10. Budesonide containing
microparticles
Eudragit RS/Eudragit
RL 70:30 (w/w)
110 lm Solvent evaporation/
spray drying
technique
Eudragit RS shows better
protection of drug from
gastric acidity than those
of Eudragit RS: Eudragit
RL
Cortesi et al. (2012)
11. Albendazole
microspheres
Eudragit RL 220 lm Solvent evaporation
method
By using Eudragit RL,
drug gets targeted to the
terminal ileum and colonic
regions
Jain et al. (2004)
Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis 467
Table 5 List of brief description of reported microparticles formulated by using various polymers by different methods.
S. No. Methods Advantages Disadvantages Applications
1. Spray drying 1. Process is rapid 1. High temperature is
required
This technique is rapid, fast.
PLGA-microparticles loaded
with thyrotropin releasing
hormone was produced by
Takada et al. (1995)
2. Formation of porous
microparticles
2. Yield is very less due to the
sticking of microparticles to
the drying chamber
3. Complete evaporation
of organic solvent
3. It can change the
polymorphism of spray dried
drugs
4. Operation is feasible
under aseptic conditions
4. Cost eﬀective
5. Both hydrophobic and
hydrophilic polymer can
be used
5. Highly viscous ﬂuids
cannot be spray dried
6. Ideal for sterile
product manufacturing
2. Single Emulsion
technique
1. Simple method 1. Chemical crosslinker is
toxic and if added in excess,
should be subjected to
centrifugation, washing and
separation, which makes it a
lengthy process
This method is used to
prepare microspheres
containing protein and
peptide drugs. Kawashima
et al. (1999) prepared nano-
spheres by using single
emulsion technique in which
insulin solution was dis-
solved in organic solvent
2. In expensive
3. Double
emulsiﬁcation
1. Controlled release 1. Stability problem is the
major disadvantage
Currently, a product named,
leuprolide acetate (a
luteinizing hormone-
releasing hormone (LHRH)
agonist was encapsulated in
form of w/o/w by using
PLGA (75/25) polymer
having MW 14 K is in
market
2. Used for hydrophilic
drugs, proteins, vaccines
2. Coalescence
4. Solvent
evaporation
1. Suitable for
microencapsulation of
lipophilic drugs like
peptide for sustained
delivery
1. Sometimes in w/o type of
emulsions, removal of oil
from ﬁnal product is
complicated
Preparation of drug
containing Poly (DL-lactide)
microparticles by solvent
evaporation method
2. Cost eﬀective
3. Use of organic solvents
like DCM which is toxic, and
need its complete removal
from ﬁnal product
4. Sometimes, protein get
denatured and formed
aggregates
5. Interfacial
polymerization
1. Fast, rapid 1. Microcapsules formed by
this method are fragile and
diﬃcult to handle
Watnasirichaikul et al.
(2000), prepared insulin
nanoparticles using this
technique2. Much controlled
approach
2. Due to large w/o interface,
enzymes or proteins get
inactivated
3. Eﬃcient 3. It’s hard to control the
polymerization reaction
4. Large no. of washing steps
are required for the complete
removal of monomers and
other by products
468 Nidhi et al.that Eudragit coated microspheres released drug from 6.25% to
8.95% in simulated gastric ﬂuid and simulated intestinal ﬂuidrespectively after 4 h, which is less as compared to simple pec-
tin-prednisolone microspheres.
Figure 3 (1) Uninﬂammed mucosa: (a) Particle size <500 nm shows endocytotic uptake, (b) particle size <5 nm shows lymphatic
uptake. (2) Inﬂammed mucosa: Increased particle uptake due to leaky epithelium.
Figure 4 Mechanism of drug release through controlling
membrane.
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containing 5-FU loaded guar gum microspheres by using
water in oil emulsiﬁcation method. In this study, in vitro drug
release was conducted at simulated gastric ﬂuid at pH 1.2 and
simulated intestinal ﬂuid at pH 7.4 and it was concluded that
capsule loaded microspheres showed low initial burst release
when compared to microsphere formulation.
7.3. Double emulsiﬁcation technique
In pharmaceutical industry, Double emulsiﬁcation technique is
mostly used for the hydrophilic drugs, proteins, vaccines, vita-
mins, enzymes for controlled release. In this technique, two
emulsions are formed, one is primary and other is secondary.
For the preparation of primary emulsion, protein aqueous
solution is dispersed in lipophilic continuous phase for the
encapsulation of protein contained in dispersed aqueous
phase. This primary phase is then homogenized and dropped
into aqueous solution of poly vinyl alcohol, which acts as sec-
ondary phase. Addition of primary phase to secondary leads to
the formation of double emulsion. The possible mechanism for
the drug release is diffusion process (Mathew et al., 2008).
Nakase et al. (2000) developed oral drug delivery system to
target macrophages with poly(DL-lactic acid) microspheres
containing dexamethasone, as a model drug by using solvent
evaporation with double emulsiﬁcation method. This study
concluded that microspheres showed therapeutic effect in
ulcerative colitis by inhibiting proinﬂammatory cytokines.
Meissner et al. (2007), prepared low molecular weight hep-
arin loaded P4135F microparticles by using double emulsion
technique with solvent evaporation method for the treatment
of ulcerative colitis.
7.4. Solvent evaporation technique
This technique is carried out for the preparation of microcap-
sules either by o/w or w/o or o/o type of emulsion. In this
method, core material is dispersed/dissolved in polymer solu-
tion. This phase is then dropped into continuous phase, in
which either water or oil is used as vehicle to obtain microcap-
sules. For the complete removal of organic solvent, heating is
necessary. Then, freeze dried the microparticles for further use.
Mateovic´-Rojnik et al., 2005 prepared Eudragit RS 100 micro-
spheres containing ketoprofen as model drug by solvent evap-
oration method.7.5. Polymerization techniques
The polymerization techniques are generally classiﬁed as (i)
normal polymerization, (ii) interfacial polymerization.
7.5.1. Normal polymerization
Various techniques are used for carrying out normal polymer-
ization such as suspension, emulsion and bulk techniques. In
suspension technique, heating of one or more monomers as
droplets dispersion is carried out in a continuous aqueous
phase. This technique is also known as bead or pearl polymer-
ization. In bulk polymerization, heating of one or more mono-
mers in the presence of catalyst takes place for the initiation of
polymerization. This type of polymerization is best for the for-
mation of pure polymers. The main example of emulsion poly-
merization is nylon microcapsules (Whateley, 1996).
7.5.2. Interfacial polymerization
In this method, two reactive monomers, one is dissolved while
other is dispersed separately in two immiscible liquids. A brisk
reaction occurs at the interface between two solutions, which
creates a thin interfacial polymer ﬁlm.
8. Mechanism of drug release of microparticles
Theoretically, there are different mechanisms of drug release of
microparticulate systems.
8.1. Diffusion controlled reservoir system
In this system, a controlling membrane is present around drug,
through which drug starts diffusing out. Here, release rate is
not affected by matrix degradation. After complete diffusion,
Figure 5 Mechanism of drug release through polymer matrix.
470 Nidhi et al.membrane gets eroded. Fig. 4 shows diffusion of drug through
controlling membrane.
8.2. Diffusion controlled monolithic system
In this system, drug is dispersed in polymer matrix. With deg-
radation of polymer matrix, drug starts diffusing out. Here,
release rate is highly affected by matrix degradation. Fig. 5
shows diffusion of drug through polymer matrix.
8.3. Degradation controlled monolithic system
In this system, drug is uniformly dispersed in polymer matrix
and rate of diffusion depends upon degradation of matrix.
Generally, rate of diffusion is slow as compared with degrada-
tion of matrix. The formula for calculating release of sphere is
governed by following equation:
Mt=M1 ¼ 1 ½ð1 t=t1Þ3
where Mt is amount of drug released at time t; M1 is amount
at time t1 for total erosion (Keerthi et al.)
8.4. Conclusion and future prospectives
With increasing new technologies, a signiﬁcant progress has
been made in developing a truly selective system for targeting
drug to site of action in ulcerative colitis. However, there is the
lack of commercial products especially biologic drugs for the
treatment of ulcerative colitis. In this respect, Foong et al.
(2010) formulated inﬂiximab loaded PLGA microspheres for
the treatment of Crohn’s disease ﬁstulae. At present, no micro-
encapsulated probiotic cells exist in market. Thus, search is
increasing on new delivery strategies that can provide the ther-
apeutic beneﬁcial to colitis suffered patients.
It has been concluded from above study that microparticu-
late carrier system appears to be the most promising approach
by speciﬁcally accumulating in inﬂamed intestinal region.
Combined approach of both pH dependent and time depen-
dent particulate systems is strongly appealing to use in a truly
colon speciﬁc drug delivery system. It may reduce the side-
effects of drug caused by absorption from stomach when given
in form of tablets. But still, there are several issues, which need
to be sorted out with regard to stability during gastric and
small intestinal passage by using this particulate carrier system.
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